Építés alatt – nem éles oldal
Belépés
Résztvevőt keresFázis nélkül

Evaluation of the Valiant Captivia Physician Fenestrated Stent Graft System in Aortic Arch and Descending Thoracic Aorta Pathologies

A legfontosabb adatok

Ki végzi
Ceric Sàrl
Hol
Franciaország4 helyszín, 1 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Toboroz
Résztvevők
30 fő, tervezett
Kezdés
2023. nov. 21.
Várható befejezés
2027. okt.
A vizsgálat típusa
Beavatkozással járó
A vizsgált kezelések
  • The Valiant Captivia Stent Graft
A regiszteradat frissítve
2024. május 1.

Ki vehet részt

Életkor
18 év felett
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 80 feltétel megnézéseKevesebb

Ki vehet részt

  • TAA/PAU (Thoracic Aortic Aneurysms and Penetrating Ulcers):
  • Subject is at least 18 years of age
  • Subject understands and has signed an Informed Consent approved by the Sponsor for this study
  • Subject must be considered a candidate for revascularisation of BT, LCCA and LSA
  • Subject must be able to tolerate surgical revascularisation of BT, LCCA and LSA
  • Subject has a TAA/PAU which is:; a fusiform aneurysm with a diameter of ≥ 5.5 cm OR is > 2 times the diameter of the non-aneurysmal thoracic aorta; AND/OR; a saccular aneurysm or PAU (ulcer defined as ≥ 10 mm in depth and 20 mm in diameter, or symptomatic)
  • Subject has a healthy, non-diseased aortic proximal seal zone of at least 20 mm
  • Subject has no thrombus in the proximal neck
  • Subject has a non-diseased aortic diameter between 25 mm and 42 mm and max diameter of the ascending aorta is ≤ 40 mm
  • Subject has a non-diseased LSA which is eligible for stent-grafting
  • Subject has sufficient landing zone within the LSA to accommodate the stent-graft without occlusion of any significant vessels
  • Brachial, iliac or femoral artery access vessel morphology (diameter, calcification, tortuosity) that is compatible with vascular access techniques, the device, or accessories
  • Symptomatic patient who needs semi urgent repair; aptient is at high surgical risk and cannot wait for 6-8 weeks for a custom-made stent graft
  • Subject is affiliated with the social security system
  • TBAD(Type B Dissections) and Residual dissection after Type A repair:
  • Subject is at least 18 years of age
  • Subject understands and has signed an Informed Consent approved by the Sponsor for this study
  • a) Subject has a degenerative aortic arch aneurysm which will require coverage of the LSA and extension of the proximal seal zone to zone 0 And/or b) Subject has a complicated TBAD (acute, subacute or chronic) which will require coverage of the LSA and extension of the proximal seal zone to zone 0 And/or c) Subject has a complicated residual dissection after replacement of the ascending aorta for type A aortic dissection which will require coverage of the LSA and extension of the proximal seal zone to zone 0
  • Subject has a healthy, non-diseased (without thrombus) aortic proximal seal zone of at least 20 mm
  • Subject has a healthy, non-diseased (without thrombus) aortic distal seal zone of at least 20 mm
  • Subject has a maximum diameter of the distal ascending aorta just above the BT of 40 mm
  • Subject has a non-diseased aortic diameter between 28 mm to 42 mm and the ascending aorta ≤ 40 m
  • Subject has a no atheromatous lesions int the arch and the BT, LCCA and LSA
  • Brachial, iliac or femoral artery access vessel morphology (diameter, calcification, tortuosity) that is compatible with vascular access techniques, the device, or accessories
  • Symptomatic patient who needs semi urgent repair; aptient is at high surgical risk and cannot wait for 6-8 weeks for a custom-made stent graft
  • Subject is affiliated with the social security system

Ki nem vehet részt

  • Subject has circumferential calcification in the common femoral or external iliac artery or in the common iliac artery with an intraluminal diameter (ID) less than 9 mm at any point proximal to or at the access vessel site unless a surgical adjunctive procedure is planned
  • Subject has had previous endovascular repair of the ascending
  • Subject has coronary artery disease with unstable angina and who has not received treatment
  • Subject is currently participating in an investigational drug or device clinical trial that would interfere with the observations of this study
  • Subject has had previous surgical or endovascular treatment of an infra-renal aortic aneurysm <30 days of implantation of investigational device
  • Subject has circumferential calcification in the common femoral artery, external iliac artery or in the common iliac artery with an intraluminal diameter (ID) less than 9 mm at any point proximal to or at the access vessel site unless a surgical adjunctive procedure is planned
  • Subject has had previous endovascular repair of the ascending, arch
  • Subject has coronary artery disease with unstable angina and who has not received treatment
  • Subject is currently participating in an investigational drug or device clinical trial that would interfere with the observationsof this study
  • Subject has had previous surgical or endovascular treatment of an infra-renal aortic aneurysm <30 days of implantation of investigational device
  • Subject has prohibitive calcification, occlusive disease, or tortuosity of intended sealing sites
  • Subject has a known allergy or intolerance to the device components
  • Subject is in acute renal failure
  • Subject has a connective tissue disease (e.g. Marfan's syndrome, medial degeneration)
  • Subject has active systemic infection and/or a mycotic aneurysm
  • Subject has a history of bleeding diathesis, coagulopathy, or refuses blood transfusion
  • Subject has had a myocardial infarction (MI) within 3 months
  • Subject has a known hypersensitivity or contraindication to anticoagulants or contrast media, which is not amenable to pre-treatment
  • Subject has prohibitive calcification, occlusive disease, or tortuosity of intended sealing sites
  • Subject has a known allergy or intolerance to the device components
  • Subject is in acute renal failure
  • Subject has a connective tissue disease (e.g. Marfan's syndrome, medial degeneration)
  • Subject has active systemic infection and/or a mycotic aneurysm
  • Subject has a history of bleeding diathesis, coagulopathy, or refuses blood transfusion
  • Subject has had a myocardial infarction (MI) within 3 months
  • Subject has a known hypersensitivity or contraindication to anticoagulants or contrast media, which is not amenable to pre-treatment; -
  • (Thoracic Aortic Aneurysms and Penetrating Ulcers, TAA/PAU):
  • Subject has an aneurysmal, tortuous, or atherosclerotic LSA
  • Subject has an aneurysmal, tortuous, or atherosclerotic LCCA
  • Subject has an aneurysmal, tortuous, or atherosclerotic BT
  • Subject has an ascending aorta diameter > 40 mm
  • Subject has thrombus in the proximal neck
  • Subject has an emergent need of treatment of the aortic pathology
  • Subject has an aortic atheroma classified as grade IV or grade V
  • Subject has significant and/or circumferential aortic mural thrombus at either the proximal or distal attachment sites that would compromise sealing of the device
  • Subject is pregnant
  • Subject has a body habitus which prevents adequate visualisation of the aorta
  • Subject has other medical, social, or psychological problems that, in the opinion of the investigator, will interfere with treatment and follow-up procedures
  • Subject has a life expectancy of less than 2 years year
  • Subject requires treatment of an infrarenal aneurysm at the time of the implantation
  • Subject has had a cerebral vascular accident (CVA) within 3 months
  • (Type B Dissections, TBAD and residual dissection after Type A repair):
  • Subject has an aneurysmal, tortuous, or atherosclerotic LCCA
  • Subject has an aneurysmal, tortuous, or atherosclerotic LSA
  • Subject has an aneurysmal, tortuous, or atherosclerotic BT
  • Subject has a dissected BT and or LCCA
  • Subject has an aortic atheroma classified as grade IV or grade V
  • Subject has significant and/or circumferential aortic mural thrombus at either the proximal or distal sealing sites that would compromise seal of the device
  • Subject is pregnant
  • Subject has a body habitus which prevents adequate visualisation of the aorta
  • Subject has other medical, social, or psychological problems that, in the opinion of the investigator, will interfere with treatment and follow-up procedures
  • Subject has a life expectancy of less than 2 years
  • Subject requires treatment of an infrarenal aneurysm at the time of the implantation
  • Subject has had a cerebral vascular accident (CVA) within 3 months

Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

The study objectives are to assess safety and effectiveness, measured acutely and at the 30-day visit after implantation of the Valiant Captivia physician fenestrated Stent Graft.

A teljes eredeti leírásKevesebb

Clinical utility measures throughout the procedure and until discharge will be assessed

A vizsgálat csoportja

  • Intervention/TreatmentA vizsgált kezelés

    The Valiant Captivia physician fenestrated stent graft for the treatment of aneurysms/penetrating ulcers, Type B aortic dissections or residual dissection after Type A repair, of the aortic arch and the descending thoracic aorta which are candidates for revascularisation of all three supra-aortic vessels (BT, LCCA, LSA)

    Kezelés: The Valiant Captivia Stent Graft

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
A regiszteradat frissítve
2024. május 1.